Overview

Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas

Status:
Terminated
Trial end date:
2018-02-14
Target enrollment:
Participant gender:
Summary
This is a pilot study to determine if adults and children with neurofibromatosis type 1 who have plexiform tumors given Sutent® respond to this drug therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Indiana University
Collaborators:
Pfizer
United States Department of Defense
Treatments:
Sunitinib